

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently amended) A composition comprising a preponderance of cis doxepin isomer over trans doxepin isomer wherein preponderance is defined as at least 51% cis relative to trans, said cis doxepin isomer being present in an amount of about 0.01% to about 10.0% by weight, and a pharmaceutically acceptable vehicle, said composition for use in the treatment of affective, painful, allergic disorders, said composition being comparable in efficacy to compositions containing a preponderance of the trans doxepin isomer but with significantly less sedative effects.
2. (Original) The composition of claim 1 wherein said composition is suitable for application to the skin.
3. (Original) The composition of claim 2 wherein said vehicle is selected from the group consisting of a lotion, a solution, a cream, an ointment, a gel, or a paste.
4. (Original) The composition of claim 1 wherein said composition is suitable for application to mucous membranes.
5. (Original) The composition of claim 4 wherein said vehicle is selected from the group consisting of solutions, suspensions, suppositories, and plasticized formulations.
6. (Original) The composition of claim 1 wherein said composition is suitable for injection.
7. (Original) The composition of claim 1 wherein said cis doxepin isomer is present in the amount of about 0.05% to about 5.0% by weight.
8. (Withdrawn) A method of treating affective, painful or allergic disorders comprising treatment with an effective amount of a composition containing a preponderance of cis doxepin isomer over trans doxepin isomer, said cis doxepin isomer being present in an amount of about 0.01% to about 10.0% by weight in a pharmaceutically acceptable vehicle, said composition being comparable in efficacy to compositions containing a preponderance of the trans doxepin isomer but with significantly less sedation.
9. (Withdrawn) The method of claim 8 wherein said method of treatment is selected from the group consisting of application to skin, application to mucous membranes and injection.
10. (Withdrawn) The method of claim 8 wherein said cis doxepin isomer is present in the amount of about 0.05-5.0% by weight.
11. (Currently amended) A composition suitable for oral administration comprising a pharmaceutically acceptable vehicle in the form of capsules, tablets, liquid solutions or

suspensions and containing a preponderance of cis doxepin isomer over trans doxepin isomer, wherein preponderance is defined as at least 51% cis relative to trans, said cis doxepin isomer present in an amount of about 0.5-500.0 mg per capsule, tablet or 5 ml portion of liquid, said composition being comparable in efficacy to compositions containing a preponderance of the trans doxepin isomer but with significantly less sedative side effects.

12. (Original) The composition of claim 11 wherein said cis doxepin isomer is present in the amount of about 1.0-50.0 mg per capsule, tablet, or 5 ml portion of liquid.
13. (Withdrawn) A method of treating affective, painful, or allergic disorders by oral administration and comprising treatment with an effective amount of a composition containing a preponderance of cis doxepin isomer over trans doxepin isomer, said cis doxepin isomer being present in an amount of about 0.5-500.0 mg per dose or 5 ml portion of liquid in a pharmaceutically acceptable vehicle, said composition being comparable in efficacy to compositions containing a preponderance of trans doxepin isomer but with significantly less sedative side effects.
14. (Withdrawn) The method of claim 13 wherein said cis doxepin isomer is present in the amount of about 1.0-50.0 mg per dose.